One of Japan's richest man is 'racing' to fulfill billions of dollar funding 'promise' to Sam Altman after selling stake worth billions in these American companies

SoftBank is racing to finalize a reported $22.5 billion funding commitment to OpenAI by year-end, using a mix of asset sales, margin loans and balance-sheet cash. The group has already sold its $5.8 billion Nvidia stake and $4.8 billion of T-Mobile stock, instituted headcount cuts, slowed Vision Fund deal activity (requiring Son's sign-off for deals >$50m) and is preparing a PayPay IPO expected to raise over $20 billion (pushed into Q1 2026). Part of the capital will support the Stargate JV with OpenAI and Oracle to build U.S. AI infrastructure, while SoftBank also looks to exit portions of its Didi stake ahead of a Hong Kong listing.

Analysis

Market structure: SoftBank's reported push to fund OpenAI ($22.5bn) by year-end creates immediate winners (OpenAI, Oracle (ORCL) as Stargate partner) and near-term losers (large-cap liquid holdings like Nvidia (NVDA) due to a reported $5.8bn stake sale). A concentrated sell program from SoftBank can transiently depress NVDA share price and raise volatility in US mega-cap tech; PayPay's planned ~$20bn IPO shifts liquidity demand into H1 2026 and could crowd out other tech offerings.

Risk assessment: Tail risks include forced margin liquidations at SoftBank (amplifying sell pressure), US regulatory crackdowns on AI partnerships, and a weak PayPay IPO that would pressure SoftBank liquidity. Near-term (days–weeks) expect elevated equity volatility and potential credit spread widening for SoftBank-related debt; medium-term (3–12 months) depends on PayPay IPO outcome and OpenAI commercialization metrics; long-term (1–3 years) the structural AI winner-take-most dynamic favors incumbents with compute/network scale.

Trade implications: Tactical trades: favor ORCL (enterprise/cloud exposure to Stargate) with 2–4% portfolio longs and 3–9 month call overlays; hedge with small NVDA downside protection (1–2% notional via 30–60 day put spreads) to guard against concentrated sales. Avoid adding to DIDI pre-HK listing and reduce direct SoftBank equity exposure; consider buying corporate credit protection or put options on SFTBY/9984 if stock falls >15% or CDS widens >200bps.

Contrarian angles: Consensus expects NVDA weakness; this may be overdone if market absorbs $5–6bn sales vs. NVDA free-float and continued chip demand — set buy-on-weakness rule: if NVDA drops >10% in 7–14 days, add a calibrated 1–2% long. Historical parallels (SoftBank asset firesales 2019) show recovery is possible once liquidity targets met; downside contagion risk to credit and JPY is the underpriced tail.

Key Decisions for Investors

• Establish a 2–4% long position in ORCL within 2–6 weeks, layering in on any pullback >5%; supplement with 3–9 month ORCL call options (delta ~0.35) to amplify upside tied to Stargate-related services revenue.
• Purchase NVDA 30–60 day put spreads sized to 1–2% of portfolio (e.g., short 0.5–1.0% notional via a -5%/-15% strike spread) to hedge immediate forced-sale risk; if NVDA drops >10% in 7–14 days, convert hedge into a 1–2% long position.
• Reduce direct exposure to DIDI to <1% ahead of its HK listing and refrain from participating in any new pre-IPO allocations tied to SoftBank until PayPay IPO clears (target: post H1 2026); consider short-duration event puts on DIDI if pre-IPO lockup concerns surface.
• If SoftBank ADR (SFTBY/9984.T) falls >15% or its 5y CDS widens >200bps within 30 days, allocate 0.5–1% portfolio to systemic hedges (long IG/ HY protection or buy S&P 500 3-month 5% OTM puts) to protect against cross-asset contagion.